Moderna-Merck melanoma vaccine cuts recurrence risk by half in trial
Researchers in the United States have reported promising results from a personalized cancer vaccine called intismeran autogene, developed by Moderna and Merck. The vaccine is meant for patients with high-risk melanoma whose tumours have been surgically removed. In a trial of over 1,000 patients, adding the vaccine to Merck’s immunotherapy drug Keytruda reduced the risk of cancer returning or death by 49 percent compared with Keytruda alone, and lowered the chance of the cancer spreading to distant organs or death by 59 percent.
The treatment works by training the immune system to attack mutations unique to a patient’s tumour. It uses up to nine doses of a custom‑made mRNA vaccine plus up to nine doses of Keytruda, given every six weeks. Because the vaccine is built from the individual’s tumour profile, it targets neoantigens that help the immune system recognise cancer cells.
While melanoma is less common than other skin cancers, it causes most skin‑cancer deaths. The American Cancer Society estimates about 112,000 new invasive melanoma cases and 8,510 deaths in the US for 2026. Moderna and Merck are already testing the approach in lung, bladder, kidney, pancreatic and stomach cancers, with results expected over the next one to two years. The current melanoma trial is still ongoing, and full results have not yet been released.
For Nigerians, this signals a potential future option for melanoma treatment, though the vaccine is not yet widely available. Staying informed about such advances can help patients and doctors discuss emerging therapies when they become accessible locally.